Livzon Pharmaceutical Group Secures Key Regulatory Approval for Breakthrough Schizophrenia Treatment

Date: 26 March 2026

Location: Zhuhai, China

Key Points of the Announcement

• Zhuhai Livzon Microsphere Technology Co., Ltd., a wholly-owned subsidiary of Livzon Pharmaceutical Group Inc., has received approval from the National Medical Products Administration (NMPA) to commence clinical trials for its innovative treatment, Brexpiprazole Microspheres for Injection.
• The approval enables the company to start clinical trials of this new formulation for the treatment of schizophrenia in adults.
• This product is classified as a Class 2.2 modified new chemical drug, indicating a significant innovation over existing treatments.
• The Brexpiprazole Microspheres for Injection is a long-acting, sustained-release formulation designed for once-monthly intramuscular injection.
• The company has already invested approximately RMB 7.53 million in direct research and development expenses for this drug.
• No long-acting brexpiprazole formulation has been approved for marketing globally or in China, positioning this product as a first-in-class candidate.

Details for Investors and Shareholders

• Innovative Drug Profile: Brexpiprazole Microspheres for Injection is an independently developed, next-generation antipsychotic. It acts through partial agonism of dopamine D2 and 5-HT1A receptors and antagonism of norepinephrine receptors. The company claims this drug demonstrates superior safety indicators compared to other current-generation drugs.
• Market Opportunity: While oral brexpiprazole is approved for various psychiatric conditions globally, there is currently no approved long-acting injectable brexpiprazole formulation. This new product is designed to fill a significant clinical and commercial gap, aiming to improve patient medication adherence and reduce relapse rates, which are key challenges in schizophrenia management.
• Potential First-Mover Advantage: If successful, Livzon could be the first to market with a long-acting injectable form of brexpiprazole, potentially capturing significant market share in China and possibly globally.
• Regulatory Milestone: The NMPA approval to begin clinical trials is a critical step. However, the drug must still successfully complete clinical trials and receive full regulatory approval before commercial launch.
• Financial Commitment: As of the announcement, direct R&D spending for this project stands at approximately RMB 7.53 million, highlighting Livzon’s commitment to innovation in the psychiatric drug market.

Risks and Considerations

• Uncertainty in Drug Development: The announcement cautions investors about the inherent risks in pharmaceutical R&D. Progression from clinical trials to eventual product launch is lengthy and uncertain, with no guarantee of success.
• Market Competition: The future competitive landscape for long-acting antipsychotic treatments remains uncertain. Investors should monitor developments closely as other companies may also pursue similar products.
• Regulatory Risks: Final approval for manufacturing and marketing is contingent on successful trial outcomes and subsequent NMPA review.

Management and Corporate Information

The announcement was signed by Liu Ning, Company Secretary. The Board includes Vice Chairman Mr. Tang Yanggang, Chairman Mr. Zhu Baoguo, several Non-Executive, Employee Representative, and Independent Non-Executive Directors, reflecting strong governance structures.

Implications for Shareholders

This development is potentially price-sensitive as it marks a significant milestone in Livzon’s pipeline and positions the company at the forefront of innovation in schizophrenia treatment in China. If clinical trials are successful and the drug is approved for marketing, Livzon could benefit from a first-mover advantage in a substantial unmet market, which may have a positive impact on its future revenues and share value. However, investors should be aware of the typical risks associated with drug development, including trial failure and regulatory delays.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consider their own risk tolerance and consult with a financial advisor before making investment decisions. The information is based on the company’s official announcement and may be subject to change as new data emerges.

View LIVZON PHARMA Historical chart here